IL21 and IL21R polymorphisms and their interactive effects on serum IL-21 and IgE levels in patients with chronic hepatitis B virus infection

Human Immunology

Volumn 74, Issue 5, 2013, Pages 567-573

  Li, Na ^a   Zhu, Qianqian ^a   Li, Zhu ^a   Han, Qunying ^a   Chen, Jinghong ^a   Lv, Yi ^a   Wang, Yawen ^a   Zeng, Xiaoyan ^a   Chen, Yanping ^a   Yang, Cuiling ^a   Liu, Zhengwen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; EQUILIBRIUM CONSTANT; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HAPLOTYPE; HEPATITIS B; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN POLYMORPHISM; SERUM;

ADULT; ALLELES; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULIN E; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-21; YOUNG ADULT;

EID: 84876302786     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.01.005     Document Type: Article

References (41)

1. Tan A.T., Loggi E., Boni C., Chia A., Gehring A.J., Sastry K.S., et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol 2008, 82(22):10986-10997.
2. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000, 191(8):1269-1280.
3. Ettinger R., Kuchen S., Lipsky P.E. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008, 223:60-86.
4. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408(6808):57-63.
5. Mitoma H., Horiuchi T., Kimoto Y., Tsukamoto H., Uchino A., Tamimoto Y., et al. Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med 2005, 16(4):609-615.
6. Brandt K., Bulfone-Paus S., Foster D.C., Rückert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003, 102(12):4090-4098.
7. Konforte D., Simard N., Paige C.J. IL-21: an executor of B cell fate. J Immunol 2009, 182(4):1781-1787.
8. Kobayashi S., Haruo N., Sugane K., Ochs H.D., Agematsu K. Interleukin-21 stimulates B-cell immunoglobulin E synthesis in human beings concomitantly with activation-induced cytidine deaminase expression and differentiation into plasma cells. Hum Immunol 2009, 70(1):35-40.
9. Wood N., Bourque K., Donaldson D.D., Collins M., Vercelli D., Goldman S.J., et al. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol 2004, 231(1-2):133-145.
10. Mehta D.S., Wurster A.L., Grusby M.J. Biology of IL-21 and the IL-21 receptor. Immunol Rev 2004, 202:84-95.
11. Sawalha A.H., Kaufman K.M., Kelly J.A., Adler A.J., Aberle T., Kilpatrick J., et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008, 67(4):458-461.
12. Webb R., Merrill J.T., Kelly J.A., Sestak A., Kaufman K.M., Langefeld C.D., et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009, 60(8):2402-2407.
13. Hecker M., Bohnert A., König I.R., Bein G., Hackstein H. Novel genetic variation of human interleukin-21 receptor is associated with elevated IgE levels in females. Genes Immun 2003, 4(3):228-233.
14. Pène J., Guglielmi L., Gauchat J.F., Harrer N., Woisetschläger M., Boulay V., et al. IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene. J Immunol 2006, 177(8):5006-5013.
15. Yang P.L., Althage A., Chung J., Maier H., Wieland S., Isogawa M., et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 2010, 107(2):798-802.
16. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81(8):4215-4225.
17. Das A., Hoare M., Davies N., Lopes A.R., Dunn C., Kennedy P.T., et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008, 205(9):2111-2124.
18. Oliviero B., Cerino A., Varchetta S., Paudice E., Pai S., Ludovisi S., et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol 2011, 55(1):53-60.
19. Levo Y., Shalit M. Serum IgE levels in patients with liver disease. Ann Allergy 1981, 47(6):456-459.
20. Gutiérrez D., Guardia P., Delgado J., Gutiérrez J., Monteseirin F.J., de la Calle A., et al. Increased serum IgE in acute type A, B and delta hepatitis. J Investig Allergol Clin Immunol 1997, 7(2):119-121.
21. Abbott W., Gane E., Winship I., Munn S., Tukuitonga C. Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians. Immunogenetics 2007, 59(3):187-195.
22. Publicover J., Goodsell A., Nishimura S., Vilarinho S., Wang Z.E., Avanesyan L., et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011, 121(3):1154-1162.
23. Ma S.W., Huang X., Li Y.Y., Tang L.B., Sun X.F., Jiang X.T., et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012, 56(4):775-781.
24. Hu X., Ma S., Huang X., Jiang X., Zhu X., Gao H., et al. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat 2011, 18(7):458-467.
25. Li N., Zhu Q., Li Z., Han Q., Zhang G., Chen J., et al. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Mol Carcinog 2012, 10.1002/mc.21992.
26. Sorrell M.F., Belongia E.A., Costa J., Gareen I.F., Grem J.L., Inadomi J.M., et al. National institutes of health consensus development conference statement: management of hepatitis B. Hepatology 2009, 49(Suppl. 5):S4-S12.
27. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
28. Li Z., Zhang Z., He Z., Tang W., Li T., Zeng Z., et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis. Cell Res 2009, 19(4):519-523. (http://analysis.bio-x.cn).
29. Lit L.C., Wong C.K., Li E.K., Tam L.S., Lam C.W., Lo Y.M. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2007, 34(1):89-96.
30. Milich D.R., Peterson D.L., Schödel F., Jones J.E., Hughes J.L. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. J Virol 1995, 69(5):2776-2785.
31. Tsai S.L., Sheen I.S., Chien R.N., Chu C.M., Huang H.C., Chuang Y.L., et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci 2003, 10(1):120-135.
32. Elsaesser H., Sauer K., Brooks D.G. IL-21 is required to control chronic viral infection. Science 2009, 324(5934):1569-1572.
33. Yi J.S., Du M., Zajac A.J. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009, 324(5934):1572-1576.
34. Fröhlich A., Kisielow J., Schmitz I., Freigang S., Shamshiev A.T., Weber J., et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009, 324(5934):1576-1580.
35. Wright T.L. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006, 101(Suppl. 1):S1-S6.
36. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., Carson W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006, 177(1):120-129.
37. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012, 7(1):e30264.
38. Agarwal S.K., Marshall G.D. In vivo alteration in type-1 and type-2 cytokine balance. a possible mechanism for elevated total IgE in HIV-infected patients. Hum Immunol 1998, 59(2):99-105.
39. de Asis M.L., Rosenstreich D.L., Chang C.J., Gourevitch M.N., Small C.B. Effect of prior hepatitis B infection on serum IgE levels in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol 1998, 80(1):35-38.
40. Zou M., Li M.M., Huang S.B., Li X.J., Zhou Y.P., Liu S.W. The detection of anti-nuclear antibody and IL-21 in patients infected with hepatitis C virus. Chin J Cell Mol Immunol 2010, 26(5):471-472.
41. Iannello A., Tremblay C., Routy J.P., Boulassel M.R., Toma E., Ahmad A. Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts. Viral Immunol 2008, 21(3):385-388.